Accession Number: | 0001209191-22-038582 |
Date: | 2022-06-17 |
Issuer: | VERA THERAPEUTICS, INC. (VERA) |
Original Submission Date: |
CURLEY JOANNE
C/O VERA THERAPEUTICS, INC.
8000 MARINA BOULEVARD, SUITE 120
BRISBANE, CA 94005
Title of Security | Transaction Date | 2a. Deemed Execution Date | Transaction Code | Shares | Acquired or Disposed | Price per share | 5. Amount of Securities Beneficially Owned Following Reported Transaction | 6. Ownership Form Direct or Indirect | Nature of Indirect Ownership |
---|---|---|---|---|---|---|---|---|---|
CLASS A COMMON STOCK | 2022-06-17 | M | 1,346 | a | $6.37 | 26,540 | direct | ||
CLASS A COMMON STOCK | 2022-06-17 | S | 1,346 | d | $15.08 | 25,194 | direct | ||
CLASS A COMMON STOCK | 2022-06-17 | M | 3,341 | a | $2.90 | 28,535 | direct | ||
CLASS A COMMON STOCK | 2022-06-17 | S | 3,341 | d | $15.03 | 25,194 | direct | ||
CLASS A COMMON STOCK | 2022-06-17 | S | 1,200 | d | $15.05 | 23,994 | direct |
Title of Derivative Security | Conversion or Exercise Price of Derivative Security | Transaction Date | Deemed Execution Date | Transaction Code | Number of Derivative Securities Acquired (A) or Disposed of (D) | Date Exercisable | Expiration Date | Title and Amount of Securities Underlying Derivative Security | Price of Derivative Security | Number of derivative Securities Beneficially Owned Following Reported Transaction(s) | Ownership Form: Direct (D) or Indirect (I) | Nature of Indirect Beneficial Ownership |
---|---|---|---|---|---|---|---|---|---|---|---|---|
STOCK OPTION (RIGHT TO BUY) | 6.3728 | 2022-06-17 | deemed execution date | M | 1,346 (d) | 2030-03-31 | class a common stock 1,346 | $6.37 | 24,145 | direct | ||
STOCK OPTION (RIGHT TO BUY) | 2.8968 | 2022-06-17 | deemed execution date | M | 3,341 (d) | 2030-12-15 | class a common stock 3,341 | $2.90 | 62,681 | direct |
ID | footnote |
---|---|
f1 | the sales reported in this form 4 were effected pursuant to a rule 10b5-1 trading plan adopted by the reporting person on april 13, 2022. |
f2 | the price reported is a weighted-average price. these shares were sold in multiple transactions at prices ranging from $15.00 to $15.33, inclusive. the reporting person will provide upon request to the staff of the securities and exchange commission, the issuer or any security holder of the issuer, full information regarding the number of shares sold at each separate price. |
f3 | the price reported is a weighted-average price. these shares were sold in multiple transactions at prices ranging from $15.00 to $15.26, inclusive. the reporting person will provide upon request to the staff of the securities and exchange commission, the issuer or any security holder of the issuer, full information regarding the number of shares sold at each separate price. |
f4 | the price reported is a weighted-average price. these shares were sold in multiple transactions at prices ranging from $15.00 to $15.21, inclusive. the reporting person will provide upon request to the staff of the securities and exchange commission, the issuer or any security holder of the issuer, full information regarding the number of shares sold at each separate price. |
f5 | 1/4 of the shares subject to the option vested on march 12, 2021, and 1/48 of the shares vest monthly thereafter. |
f6 | 1/4 of the shares subject to the option vest on december 16, 2021, and 1/48 of the shares vest monthly thereafter. |